Jin-Yuan Shih - Search Results

Year	Number of Results
2002	2
2003	2
2004	3
2005	8
2006	5
2007	6
2008	14
2009	4
2010	16
2011	19
2012	14
2013	6
2014	7
2015	15
2016	12
2017	19
2018	19
2019	18
2020	25
2021	25
2022	12
2023	20
2024	9

1

Next-generation sequencing reveals genetic heterogeneity and resistance mechanisms in patients with EGFR-mutated non-small cell lung cancer treated with afatinib.

Liang SK, Wei PF, Hsieh MS, Wu CL, Shih JY. Liang SK, et al. Among authors: shih jy. ERJ Open Res. 2024 Mar 18;10(2):00676-2023. doi: 10.1183/23120541.00676-2023. eCollection 2024 Mar. ERJ Open Res. 2024. PMID: 38500795 Free PMC article.

2

Dual-energy computed tomography for evaluating nodal staging in lung adenocarcinoma: correlation with surgical pathology.

Huang HC, Huang YS, Chang YC, Shih JY, Chen JS, Chang YC, Wang TC. Huang HC, et al. Among authors: shih jy. Jpn J Radiol. 2024 May;42(5):468-475. doi: 10.1007/s11604-023-01525-9. Epub 2024 Feb 5. Jpn J Radiol. 2024. PMID: 38311704

3

RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19 Deletion Variants.

Nishino K, Shih JY, Nakagawa K, Reck M, Garon EB, Carlsen M, Matsui T, Visseren-Grul C, Nadal E. Nishino K, et al. Among authors: shih jy. JTO Clin Res Rep. 2023 Dec 19;5(2):100624. doi: 10.1016/j.jtocrr.2023.100624. eCollection 2024 Feb. JTO Clin Res Rep. 2023. PMID: 38304857 Free PMC article.

4

Real-world evidence of lorlatinib therapy in Taiwanese patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer.

Shih JY, Luo YH, Chang GC, Chang JW, Wang CC, Yang TY, Fang WT, Shau WY. Shih JY, et al. J Formos Med Assoc. 2024 Jan 8:S0929-6646(23)00499-0. doi: 10.1016/j.jfma.2023.12.019. Online ahead of print. J Formos Med Assoc. 2024. PMID: 38195317 Free article.

5

Comprehensive Genomic Analysis of Patients With Non-Small-Cell Lung Cancer Using Blood-Based Circulating Tumor DNA Assay: Findings From the BFAST Database of a Single Center in Taiwan.

Wang HY, Ho CC, Lin YT, Liao WY, Chen CY, Shih JY, Yu CJ. Wang HY, et al. Among authors: shih jy. JCO Precis Oncol. 2024 Jan;8:e2300314. doi: 10.1200/PO.23.00314. JCO Precis Oncol. 2024. PMID: 38190582 Free PMC article.

6

Tissue or liquid rebiopsy? A prospective study for simultaneous tissue and liquid NGS after first-line EGFR inhibitor resistance in lung cancer.

Lin YT, Ho CC, Hsu WH, Liao WY, Yang CY, Yu CJ, Tsai TH, Yang JC, Wu SG, Hsu CL, Hsieh MS, Huang YL, Wu CL, Shih JY. Lin YT, et al. Among authors: shih jy. Cancer Med. 2023 Dec 22;13(1):e6870. doi: 10.1002/cam4.6870. Online ahead of print. Cancer Med. 2023. PMID: 38140788 Free PMC article.

7

miR-204 suppresses cancer stemness and enhances osimertinib sensitivity in non-small cell lung cancer by targeting CD44.

Wu SG, Chang TH, Tsai MF, Liu YN, Huang YL, Hsu CL, Jheng HN, Shih JY. Wu SG, et al. Among authors: shih jy. Mol Ther Nucleic Acids. 2023 Dec 5;35(1):102091. doi: 10.1016/j.omtn.2023.102091. eCollection 2024 Mar 12. Mol Ther Nucleic Acids. 2023. PMID: 38130372 Free PMC article.

8

CD44s and CD44v8-10 isoforms confer acquired resistance to osimertinib by activating the ErbB3/STAT3 signaling pathway.

Liu YN, Tsai MF, Wu SG, Chang TH, Shih JY. Liu YN, et al. Among authors: shih jy. Life Sci. 2024 Jan 1;336:122345. doi: 10.1016/j.lfs.2023.122345. Epub 2023 Dec 11. Life Sci. 2024. PMID: 38092140

9

Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan: a prospective cohort study.

Chang GC, Chiu CH, Yu CJ, Chang YC, Chang YH, Hsu KH, Wu YC, Chen CY, Hsu HH, Wu MT, Yang CT, Chong IW, Lin YC, Hsia TC, Lin MC, Su WC, Lin CB, Lee KY, Wei YF, Lan GY, Chan WP, Wang KL, Wu MH, Tsai HH, Chian CF, Lai RS, Shih JY, Wang CL, Hsu JS, Chen KC, Chen CK, Hsia JY, Peng CK, Tang EK, Hsu CL, Chou TY, Shen WC, Tsai YH, Tsai CM, Chen YM, Lee YC, Chen HY, Yu SL, Chen CJ, Wan YL, Hsiung CA, Yang PC; TALENT Investigators. Chang GC, et al. Among authors: shih jy. Lancet Respir Med. 2024 Feb;12(2):141-152. doi: 10.1016/S2213-2600(23)00338-7. Epub 2023 Nov 29. Lancet Respir Med. 2024. PMID: 38042167

10

Effects of Early Short-Course Corticosteroids on Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.

Huang DD, Liao BC, Hsu WH, Yang CY, Lin YT, Wu SG, Tsai TH, Chen KY, Ho CC, Liao WY, Shih JY, Yu CJ, Yang JC, Cheng AL, Shen YC. Huang DD, et al. Among authors: shih jy. Oncology. 2024;102(4):318-326. doi: 10.1159/000534350. Epub 2023 Sep 29. Oncology. 2024. PMID: 37778345 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

239 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

239 results

Results by year